Eicosanoids pp 183-193 | Cite as

PGI2 and Its Analogs: From Pharmacology to Therapeutic Applications

  • S. Nicosia
Chapter
Part of the NATO ASI Series book series (NSSA, volume 283)

Abstract

Prostacyclin (PGI2), biosynthesized in vivo by many tissues and particularly by the vascular endothelium, is endowed with a number of potentially interesting physiological and pharmacological properties (Moncada & Vane, 1979; Oates et al. 1988a, b; Dusting & MacDonald, 1990). Indeed, PGI2 is able to:
  • Inhibit all aspects of platelet activation, inlcuding aggregation, shape change, adhesion, release of procoagulant factors and release from dense bodies and α-granules

  • Dilate arteries, veins, arterioles, while being much less potent on venules

  • “Cytoprotect” not only the gastrointestinal system, but also platelets, neutrophils, liver, myocardium and other tissues

  • Inhibit the activation of polymorphonuclear leukocytes, although at concentrations higher than those active on either platelets or vasculature

  • Favour fibrinolysis

  • Mediate renin release.

Keywords

Peripheral Vascular Disease Human Platelet Thrombotic Thrombocytopenic Purpura Primary Pulmonary Hypertension Hamster Cheek Pouch 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Accomazzo, M.R., Giovanazzi, S., Letari, O., Oliva, D., and Nicosia, S., 1994, Internalization of a high affinity prostacyclin receptor in human platelets, Abs., 9th International Conference on Prostaglandins and Related CompoundsGoogle Scholar
  2. Alt, U., Leigh, P. J., Wilkins, A. J., Morris, P. K. and MacDermot, J., 1986, Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro, Br. J. clin. Pharmac. 22:118–119.Google Scholar
  3. Andersen, N. H., Eggerman, T. L., Harker, L. A., Wilson, C. H. and De, B., 1980, On the multiplicity of platelet prostaglandin receptors. Evaluation of competitive antagonism by aggregometry, Prostaglandins 19:711–735.PubMedGoogle Scholar
  4. Änggård, E., 1966, The biological activities of three metabolites of prostaglandin E1, Acta physiol. scand. 66:509–510.PubMedCrossRefGoogle Scholar
  5. Ashby, B., 1990, Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets, Mol. Pharmacol. 38:46–53.PubMedGoogle Scholar
  6. Barradas, M. A., Fonseca, V. A., Mikhailidis, D. P. and Dandona, P., 1989, The effect of iloprost infusion on platelet function in patients with peripheral vascular disease, J. Drug Dev. 2:147–153.Google Scholar
  7. Barst, R. J., Rubin, L. J., McGoon, M. D., Caldwell, E. J., Long, W. A. and Levy, P. S., 1994, Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin, Ann. Intern. Med. 121:409–415.PubMedCrossRefGoogle Scholar
  8. Belch, J. J. F., 1993, Prostaglandins in Raynaud’s phenomenon, In: Therapeutic applications of prostaglandins Vane, J.R., O’Grady, J., eds. Edward Arnold, London pp. 219–239.Google Scholar
  9. Coleman, R. A., Smith, W. L. and Narumiya, S., 1994, VIII International union of pharmacology. Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes, Pharmacol. Rev. 46:205–229.PubMedGoogle Scholar
  10. Corsini, A., Folco, G. C., Fumagalli, R., Nicosia, S., Noé, M. A. and Oliva, D., 1987, (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets, Br. J. Pharmacol. 90:255–261.PubMedCrossRefGoogle Scholar
  11. Dusting, G. J. and MacDonald, P. S., 1990, Prostacyclin and vascular function: implications for hypertension and atherosclerosis, Pharmac. Ther. 48:323–344.CrossRefGoogle Scholar
  12. Eggerman, T. L., Andersen, N. H. and Robertson, R. P., 1986, Separate receptors for prostacyclin and prostaglandin E2 on human gel-filtered platelets, J. Pharmacol Exp. Ther. 236:568–573.PubMedGoogle Scholar
  13. European working group on critical leg ischemia, 1991, Second european consensus document on chronic critical leg ischemia, Circulation 84 (suppl):IV–1–IV–22.Google Scholar
  14. Fiessinger, J. N. and Schäfer, M., 1990, Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans, Lancet 335:555–557.PubMedCrossRefGoogle Scholar
  15. Fisher, C. A., Kappa, J. R., Sinha, A. K., Cottrell, E. D., Reiser, H. J. and Addonizio, V. P., 1987, Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E, on human platelet function, J. Lab. Clin. Med. 109:184–190.PubMedGoogle Scholar
  16. Fitscha, P., Kaliman, J., O’Grady, J. and Sinzinger, H., 1988, In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins, Folia Haematol. 115:443–446.Google Scholar
  17. Fitscha, P., Tiso, B., Krais, T. and Sinzinger, H., 1987, Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD), In: Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Samuelsson, B., Paoletti, R., Ramwell, P.W., eds. Raven Press, New York Vol. 17: pp. 450–454.Google Scholar
  18. Grant, S. M. and Goa, K. L., 1992, Iloprost. Areview of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures, Drugs 43:889–924.PubMedCrossRefGoogle Scholar
  19. Higenbottam, T. W., Spiegelhalter, D., Scott, J. P., Fuster, V., Dinh-Xuan, A. T., Caine, N. and Wallwork, J., 1993, Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension, Br. Heart J. 70:366–370.PubMedCrossRefGoogle Scholar
  20. Johnson, R. A., Morton, D. R., Kinner, J. H., Gorman, R. R., McGuire, J. C., Sun, F. F., Whittaker, N., Bunting, S., Salmon, J., Moncada, S. and Vane, J. R., 1976, The chemical structure of prostaglandin X (prostacyclin), Prostaglandins 12:915–928.PubMedGoogle Scholar
  21. Krause, W. and Krais, T., 1987, Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers, Eur. J. Clin. Pharmacol. 32:597–605.PubMedCrossRefGoogle Scholar
  22. Loosemore, T. M., Chalmers, T. C. and Dormandy, J. A., 1994, A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease, Int. Angiol. 13:133–142.PubMedGoogle Scholar
  23. Machin, S. J., Yardumian, D. A., O’Flynn, K. and Linch, D. C., 1987, Laboratory investigations of potentialheparin-iloprost interactions, In: Prostacyclin and its stable analogue iloprost Gryglewski, R. J., Stock, G. eds. Springer-Verlag, Berlin Heidelberg pp. 69–79.CrossRefGoogle Scholar
  24. Maderna, P., Colli, S., Sirtori, C. R., Di Minno, G. and Tremoli, E., 1990, Trial of low-doses iloprost and aspirin in normal volunteers: aspirin-induced enhancement of the platelet anti-aggregating potential of iloprost, Thromb. Haemorrh. Disorders 1:17–22.Google Scholar
  25. Matthews, J. S. and Jones, R. L., 1993, Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues, Br. J. Pharmacol. 108:363–369.PubMedCrossRefGoogle Scholar
  26. Modesti, P. A., Fortini, A., Poggesi, L., Boddi, M., Abbate, R. and Gensini, G. F., 1987, Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man, Thromb. Res. 48:663–669.PubMedCrossRefGoogle Scholar
  27. Moncada, S. and Vane, J. R., 1979, Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin, Pharmacol. Rev. 30:293–331.Google Scholar
  28. Müller, B. and Schmidtke, M., 1987, Microvascular effects of iloprost in the hamster cheek pouch, In: Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Samuelsson, B., Paoletti, R., Ramwell, P.W., eds. Raven Press, New York Vol. 17: pp. 455–458.Google Scholar
  29. Oates, J. A., FitzGerald, G. A., Branch, R. A., Jackson, E. K., Knapp, H. R. and Roberts, L. J., 1988a, Clinical implications of prostaglandin and thromboxane A2 formation (First of two parts), N. Engl. J. Med. 319:689–698.PubMedCrossRefGoogle Scholar
  30. Oates, J. A., FitzGerald, G. A., Branch, R. A., Jackson, E. K., Knapp, H. R. and Roberts, L. J., 1988b, Clinical implications of prostaglandin and thromboxane A2 formation (Second of two parts), N. Engl. J. Med. 319:761–767.PubMedCrossRefGoogle Scholar
  31. Oliva, D. and Nicosia, S., 1987, PGI2-receptors and molecular mechanisms in platelets and vasculature: state of the art, Pharmacol. Res. Commun. 19:735–765.PubMedCrossRefGoogle Scholar
  32. Rich, S., 1994, Prostacyclin and primary pulmonary hypertension, Ann. Intern. Med. 121:463–464.PubMedCrossRefGoogle Scholar
  33. Rovati, G. E., and Nicosia, S., 1994, Lower efficacy: interaction with an inhibitory receptor or partial agonism?, Trends Pharmacol Sc., 15:140–144CrossRefGoogle Scholar
  34. Samuelsson, B., Granström, E., Green, K., Hamberg, M. and Hammarström, S., 1975, Prostaglandins, In: Annual Review of Biochemistry Snell, E.E., et al., eds. Annual Reviews Inc., Palo Alto, California Vol. 44: pp. 669–695.Google Scholar
  35. Shio, H. and Ramwell, P., 1972, Effect of prostaglandin E2 and aspirin on the secondary aggregation of human platelets, Nature New Biol. 236:45–46.PubMedCrossRefGoogle Scholar
  36. Sinzinger, H., 1993, Prostaglandins in ischaemic peripheral vascular disease, In: Therapeutic applications of prostaglandins, Vane, J.R., O’Grady, J., eds. Edward Arnold, London, p. 209–218.Google Scholar
  37. Sun, F. F., Taylor, B. M., McGuire, J. C., Wong, P. Y. K., Malik, K. U. and McGiff, J. C., 1979, Metabolic disposition of prostacyclin, In: Prostacyclin, Vane, J.R., Bergström, S., eds., Raven Press New York, p. 119–131.Google Scholar
  38. Tremoli, E., Colli, S. and Paoletti, R., 1990, Mode of action of PGI2 and of its stable derivative iloprost on platelets and leukocytes, Thromb. Res. XI (Suppl):33–42.CrossRefGoogle Scholar
  39. Vane, J. R. and O’Grady, J., 1993, Therapeutic applications of prostaglandins, Edward Arnold, London.Google Scholar
  40. Wennmalm, Å, 1993, Prostaglandins in myocardial infarction and angina, In: Therapeutic applications of prostaglandins, Vane, J.R., O’Grady, J., eds., Edward Arnold, London p. 160–174.Google Scholar
  41. Whittle, B. J. R. and Moncada, S., 1984, Antithrombotic assessment and clinical potential of prostacyclin analogues, In: Progress in Medicinal Chemistry, Ellis, G.P., West, G.B., eds., Elsevier Science Publishers B.V., Amsterdam Vol. 21:pp. 238–279.Google Scholar
  42. Whittle, B. J. R., Moncada, S. and Vane, J. R., 1981, Biological activities of some metabolites and analogues of prostacyclin, In: Medicinal Chemistry Advances, De Las Heras, F.G., Vega, S., eds., Pergamon Press, Oxford, pp. 141–158.Google Scholar
  43. Witt, W. and Müller, B., 1987, Antithrombotic profile of iloprost in experimental models of in vivo platelet aggregation and thrombosis, In: Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Samuelsson, B., Paoletti, R., Ramwell, P.W., eds., Raven Press, New York, Vol. 17: pp. 279–284.Google Scholar
  44. Yardumian, D. A., Mackie, I. J., Bull, H., Goldstone, A. H. and Machin, S. J., 1985, Platelet hyperaggregability occurring during prolonged continuous intravenous infusions of prostacyclin analogue ZK 36374, Br. J.Haematol. 60:109–116.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • S. Nicosia
    • 1
  1. 1.Institute of Pharmacological SciencesUniversity of MilanMilanItaly

Personalised recommendations